TaiMed Biologics Statistics

Total Valuation

TaiMed Biologics has a market cap or net worth of TWD 22.42 billion. The enterprise value is 20.78 billion.

Market Cap	22.42B
Enterprise Value	20.78B

Important Dates

The next estimated earnings date is Tuesday, March 25, 2025.

Earnings Date	Mar 25, 2025
Ex-Dividend Date	n/a

Share Statistics

TaiMed Biologics has 273.08 million shares outstanding. The number of shares has increased by 4.15% in one year.

Current Share Class	n/a
Shares Outstanding	273.08M
Shares Change (YoY)	+4.15%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	1.45%
Owned by Institutions (%)	5.32%
Float	185.59M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	34.70
PB Ratio	5.41
P/TBV Ratio	6.26
P/FCF Ratio	151.95
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-146.68
EV / Sales	33.37
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	140.81

Financial Position

The company has a current ratio of 5.66, with a Debt / Equity ratio of 0.13.

Current Ratio	5.66
Quick Ratio	3.24
Debt / Equity	0.13
Debt / EBITDA	n/a
Debt / FCF	3.59
Interest Coverage	-11.37

Financial Efficiency

Return on equity (ROE) is -4.17% and return on invested capital (ROIC) is -2.32%.

Return on Equity (ROE)	-4.17%
Return on Assets (ROA)	-1.93%
Return on Capital (ROIC)	-2.32%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.13
Inventory Turnover	0.23

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +3.22% in the last 52 weeks. The beta is 0.32, so TaiMed Biologics's price volatility has been lower than the market average.

Beta (5Y)	0.32
52-Week Price Change	+3.22%
50-Day Moving Average	81.52
200-Day Moving Average	84.89
Relative Strength Index (RSI)	46.21
Average Volume (20 Days)	795,049

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TaiMed Biologics had revenue of TWD 622.61 million and -141.65 million in losses. Loss per share was -0.54.

Revenue	622.61M
Gross Profit	270.63M
Operating Income	-150.22M
Pretax Income	-141.65M
Net Income	-141.65M
EBITDA	-2.40M
EBIT	-150.22M
Loss Per Share	-0.54

Full Income Statement

Balance Sheet

The company has 2.17 billion in cash and 529.91 million in debt, giving a net cash position of 1.64 billion or 6.02 per share.

Cash & Cash Equivalents	2.17B
Total Debt	529.91M
Net Cash	1.64B
Net Cash Per Share	6.02
Equity (Book Value)	4.15B
Book Value Per Share	15.19
Working Capital	3.37B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 156.74 million and capital expenditures -9.19 million, giving a free cash flow of 147.55 million.

Operating Cash Flow	156.74M
Capital Expenditures	-9.19M
Free Cash Flow	147.55M
FCF Per Share	0.54

Full Cash Flow Statement

Margins

Gross margin is 43.47%, with operating and profit margins of -24.13% and -22.75%.

Gross Margin	43.47%
Operating Margin	-24.13%
Pretax Margin	-22.75%
Profit Margin	-22.75%
EBITDA Margin	-0.39%
EBIT Margin	-24.13%
FCF Margin	23.70%

Dividends & Yields

TaiMed Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.15%
Shareholder Yield	-4.15%
Earnings Yield	-0.66%
FCF Yield	0.66%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TaiMed Biologics has an Altman Z-Score of 9.04.

Altman Z-Score	9.04
Piotroski F-Score	n/a